BioCentury
ARTICLE | Clinical News

Reata gains as bardoxolone study moves to Phase III

July 24, 2017 10:44 PM UTC

Reata Pharmaceuticals Inc. (NASDAQ:RETA) gained $4.37 (14%) to $35.47 on Monday after saying it will move ahead to the Phase III portion of the Phase II/III CARDINAL study of bardoxolone methyl (RTA 402) to treat chronic kidney disease (CKD) caused by Alport syndrome.

Data from the trial's Phase II portion showed that bardoxolone improved estimated glomerular filtration rate (eGFR) by 6.9 mL/min/1.73 m^2 at Week 4 (p<0.0005) and 12.7 mL/min/1.73 m^2 at Week 12 (p<0.00005), surpassing the threshold required to begin Phase III. Bardoxolone is a small molecule activator of nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2)...

BCIQ Company Profiles

Reata Pharmaceuticals Inc.